{'fraction_non_alphanumeric': 0.024519549370444003, 'fraction_numerical': 0.009940357852882704, 'mean_word_length': 5.317991631799163, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
In silico insights on IL-6: A Potential target for Multicentric Castleman Disease.

Multicentric Castleman Disease (MCD) is a confrontational lymphoproliferative disorder described by symptoms such as lymph node proliferation, unwarranted secretion of inflammatory cytokines, hyperactive immune system, and in severe cases, multiple organs dysfunction. Interleukin-6 (IL-6) is a pleiotropic cytokine which is involved in a large range of physiological processes in our body such as pro-inflammatory, anti-inflammation, differentiation of T-cells and is reported to be a key pathological factor in MCD. In case of MCD, it is seen that IL-6 get overproduced from T-cells and macrophage which disturbs Hepcidin, a vital regulator of iron trafficking in macrophage. The present study endeavors to expound the inhibitor which binds to the IL-6 protein receptor which high affinity, through molecular docking and virtual screening. MolDock algorithm is employed to disclose the best-established drug. This compound is subjected to virtual screening against PubChem database to get inhibitors with very similar properties. The virtual screened compound PubChem CID: 101119084 is seen to possess highest affinity with target protein. Comparative studies and ADMET analysis are carried out further implicate this compound as a better inhibitor of the receptor protein. Hence, this compound recognized in the study possesses high potential as IL-6 inhibitor and should be examined for its efficiency by in vivo studies.